Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Treatment Safety Study of Talazoparib in Patients With Advanced Solid Tumors
2016-001972-31Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talazoparib in Nonhematologic neoplasms, sponsored by Pfizer. Primary endpoint: Safety. Started Jul 2016; status: completed.
02
Drugs
talazoparib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2016-001972-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001972-31.